
Anebulo Pharmaceuticals (ANEB) Stock Forecast & Price Target
Anebulo Pharmaceuticals (ANEB) Analyst Ratings
Bulls say
Anebulo Pharmaceuticals Inc is poised for potential upward momentum due to anticipated positive milestones surrounding its lead product candidate, ANEB-001, which addresses the increasing concern of cannabinoid overdose amid rising THC potency and legalization efforts. The company’s market opportunity is further bolstered by a $1.9 million cooperative grant from NIDA to develop an intravenous formulation of ANEB-001, highlighting regulatory support for its innovative approach. Clinical studies demonstrate that ANEB-001 is rapidly absorbed, well tolerated, and effectively contributes to weight loss, reinforcing its viability in treating acute cannabis overdose and enhancing the company’s growth potential.
Bears say
Anebulo Pharmaceuticals has experienced a significant decline in share value since its Initial Public Offering in May 2021, reflecting broader market trends. The company is projected to incur a net loss of $5.6 million for fiscal 2025, which represents a continuing trend of financial losses, including a reported net loss of $8.2 million for the fiscal year ending June 2024. Additionally, the decrease in losses from $11.7 million in fiscal 2023 to $8.2 million in fiscal 2024 indicates only a marginal improvement, which may raise concerns about the company’s financial sustainability and growth prospects.
This aggregate rating is based on analysts' research of Anebulo Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Anebulo Pharmaceuticals (ANEB) Analyst Forecast & Price Prediction
Start investing in Anebulo Pharmaceuticals (ANEB)
Order type
Buy in
Order amount
Est. shares
0 shares